Opinion|Videos|March 20, 2025
Treatment Selection for mCRPC
Panelists discuss how patients with bone-predominant mCRPC, good performance status, adequate bone marrow function, and limited visceral disease are ideal candidates for RAD-ENZ combination therapy, particularly when proper bone health monitoring and prophylaxis can be implemented.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Considering the safety profile and efficacy, which patients are best suited for RAD-ENZ combination therapy?
- How does the PEACE-3 data inform your discussions with patients regarding treatment expectations and outcomes?
Advertisement
Related to this article
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
4
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
5